Organigram Pulls German Medical Cannabis Unit Into Global Operating Structure

Four months after closing one of the largest transactions in European cannabis, Organigram Global is folding Berlin-based Sanity Group fully into its corporate structure — ending the standalone operating arrangement the acquisition agreement had required and elevating Sanity’s founders into the Canadian company’s top global roles.

In an announcement dated August 20, 2026, Organigram said it has appointed Sanity founder Finn Age Hänsel as President, Rest of World & Chief Strategy Officer, and Adrian Frenzel, previously Sanity’s Managing Director and COO, as Global Chief Operating Officer. Tim Emberg continues as President, Canada. The unified structure aligns leadership, operations, and market development across a network the company says will span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom, and Australia.

The Earnout, Locked In Early

Making integration possible required amending the deal’s central financial mechanism. The original share purchase agreement required Sanity Group to operate on a standalone basis during a twelve-month earnout period, with up to €120 million in additional consideration tied to defined performance metrics. The amended agreement scraps the performance test and fixes the earnout at 85% of the maximum value contemplated under the original agreement, payable on the same timeline as before.

The fixed consideration consists of €20 million in cash, with the remaining balance (net of Organigram’s pre-acquisition interests and certain other deductions) of approximately €76 million payable in Organigram common shares. The share count will be set by the 20-day volume-weighted average trading price on the Toronto Stock Exchange as of three days before payment, subject to a floor of C$3.00 and a cap of C$4.00 per share. The earnout becomes payable as of April 1, 2027, with the cash and shares to be delivered no later than May 1, 2027.

“That progress, together with our confidence in Sanity’s continued growth trajectory, makes this the right time to take the next step in our integration,” said James Yamanaka, Chief Executive Officer of Organigram. “Fixing the earnout provides greater clarity and certainty while further strengthening strategic alignment and execution across the organization.”

The company notes the amendment qualifies as a related-party transaction under Canadian securities rules but is exempt from formal valuation and minority-approval requirements, because neither the consideration nor the subject matter exceeds 25% of Organigram’s market capitalization.

What Sanity Brings to the Combined Company

Sanity contributed approximately CAD$40 million to Organigram’s consolidated net revenue in the most recent quarter (more than 35% of the total) and was accretive to Adjusted EBITDA, the companies said. Quarterly revenue at Sanity has climbed 34% since December 31, 2025, reaching €25.5 million.

Organigram’s third-quarter fiscal 2026 results, reported August 11, 2026, put the quarter’s consolidated net revenue at a record C$105.8 million, up 49% year over year, an increase the company attributed primarily to Sanity’s contribution. Adjusted EBITDA reached C$13.4 million, up 136%. The results marked the first quarter of Sanity’s financial contribution following the acquisition’s close on April 15, 2026.

For Germany’s medical cannabis market, the deal places one of the country’s largest operators inside a vertically integrated transatlantic supply chain. Sanity, founded in Berlin in 2018, runs a portfolio spanning medical cannabis brands Vayamed, avaay Medical and ZOIKS, finished-pharmaceuticals unit Endosane Pharmaceuticals, the vaay wellness line, and Grashaus Projects, its Swiss recreational pilot venture. The August 20 announcement cites a German medical cannabis market valued at more than €2 billion in 2025, serving roughly 800,000 patients, and forecast to exceed €4 billion by 2028.

The Story So Far

The integration is the latest step in a rapid consolidation between the two companies. Organigram and Sanity announced the transaction in February 2026 and closed it in mid-April 2026, at a valuation of up to €250 million: an initial €130 million plus the €120 million performance-based earnout that has now been fixed. The April closing release positioned the agreement among the largest deals in the European cannabis and healthcare sector and one of the most significant transactions in Berlin’s startup ecosystem in recent years.

Since then, the combined group has moved on several fronts. MyCannabis covered the companies’ Swiss distribution agreement in June 2026, and Organigram’s August results (the first quarter with Sanity on the books) showed Sanity advancing a second Swiss recreational pilot project, progressing its entry into Poland, launching branded products in the U.K. through new partnerships, and recording its first meaningful medical cannabis sales in Switzerland.

What Happens Next

The earnout payment date is the next fixed milestone: consideration becomes payable as of April 1, 2027, with delivery of the cash and shares due no later than May 1, 2027. Max Narr, the former Sanity managing director appointed to Organigram’s board at closing, retains that seat for the duration of the earnout period.

Operationally, Hänsel now leads Organigram’s global corporate strategy, international market development, and strategic partnerships, including evaluating entry into additional markets with the company’s brands, products, and intellectual property. Frenzel takes charge of operational performance and gross margin expansion across the consolidated business, with an initial focus on aligning the Canadian and European operating platforms. On the Canadian side, Organigram has told investors it remains on track for fiscal 2026 net revenue exceeding C$350 million, with one quarter left in its fiscal year ending September 30, 2026.